• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ther Apher Dial . Continuous Kidney Replacement Therapy and Outcomes of Severe Coronavirus Disease 2019 Treated With Extracorporeal Membrane Oxygena

tetano

Editor, Senior Moderator
Ther Apher Dial


. 2025 Aug 4.
doi: 10.1111/1744-9987.70071. Online ahead of print. Continuous Kidney Replacement Therapy and Outcomes of Severe Coronavirus Disease 2019 Treated With Extracorporeal Membrane Oxygenation

Yoshito Izutani[SUP] 1 [/SUP], Yasumasa Kawano[SUP] 1 2 [/SUP], Akihiro Fujita[SUP] 1 [/SUP], Shinichi Morimoto[SUP] 1 [/SUP], Kentaro Muranishi[SUP] 1 [/SUP], Kota Hoshino[SUP] 1 3 4 [/SUP], Junichi Maruyama[SUP] 1 [/SUP], Maiko Nakashio[SUP] 1 [/SUP], Junta Noake[SUP] 1 [/SUP], Hiroki Hatomoto[SUP] 5 [/SUP], Shintaro Yamasaki[SUP] 5 [/SUP], Kazuya Yamauchi[SUP] 5 [/SUP], Jun Hamaguchi[SUP] 6 [/SUP], Naofumi Bunya[SUP] 7 [/SUP], Ryuichi Nakayama[SUP] 7 8 [/SUP], Keiki Shimizu[SUP] 6 [/SUP], Yoshihiko Nakamura[SUP] 1 [/SUP]



Affiliations
Abstract

Introduction: Although continuous kidney replacement therapy (CKRT) for acute kidney injury (AKI) management is common, its effect on the outcomes of patients treated with extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease 2019 (COVID-19) remains unclear. Therefore, we aimed to investigate the impact of CKRT on the outcomes of these patients.
Methods: Using a database of patients with severe COVID-19 who required venovenous ECMO across three centers in Japan, we assessed demographics, clinical parameters, and in-hospital mortality rates from January 2020 to December 2021.
Results: Data of 122 patients treated with ECMO for COVID-19 were analyzed. Forty-five patients required CKRT; the in-hospital mortality rate was 28.7%. Multivariate analysis showed age and CKRT were independent risk factors for in-hospital mortality. The in-hospital mortality rate was significantly higher in the CKRT group.
Conclusion: CKRT was associated with significantly high in-hospital mortality in patients treated with ECMO for severe COVID-19.

Keywords: acute kidney injury; acute respiratory distress syndrome; continuous renal replacement therapy; extracorporeal membrane oxygenation; hospital mortality.

 
Back
Top Bottom